On February 19, 2014 Novartis announced that the pivotal trial of LDE225 (sonidegib) in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment (Press release Novartis, FEB 18, 2014, View Source [SID:1234500094]). Objective response included complete response (clinically significant tumor response with complete absence of disease) and partial response (clinically significant tumor shrinkage).
Full study results will be presented at a future scientific meeting.